Our vision is to develop pharmaceuticals that contribute to normalized lives for patients

New class of drugs for treatment of severe inflammatory conditions and resistant cancer

The fractalkine axis controls pro-inflammatory cells and cancer cells with precision

Our business

Kancera develops pharmaceuticals for life threatening diseases with high medical needs

Read More

Our science

Kancera develops a new class of drugs targeting the fractalkine axis

Read More

Our pipeline

Kancera’s two fractalkine blocking drug candidates are currently being studied in three ongoing clinical trials

Read More

CEO statement

“The outcome of the FRACTAL study is a success for Kancera. In addition to demonstrating that KAND567 is safe and tolerable we have seen clear signals of heart-protective effects that are or high clinical relevance.”

Peter Selin, CEO Kancera